SS-31 Research Profile

The interest surrounding SS-31 is primarily rooted in mitochondrial biology. Mitochondria are responsible for much of the cell’s ATP production, but they also have a less glamorous side: when their structure or energy-producing machinery becomes disrupted, oxidative stress, altered membrane function and cellular damage can follow. Researchers have therefore been looking at ways of protecting mitochondrial structure rather than simply trying to deal with oxidative stress after the fact.

SS-31 is one of the compounds developed around that idea.

What exactly is SS-31?

SS-31 is a synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH₂. Its unusual combination of aromatic and positively charged residues gives it properties that allow it to cross cell membranes and accumulate within mitochondria. Importantly, its mitochondrial targeting does not depend on a normal mitochondrial membrane potential in the same way as some other mitochondria-directed compounds.

Once inside the mitochondria, SS-31 has a particular affinity for cardiolipin.

Cardiolipin is a distinctive phospholipid found mainly in the inner mitochondrial membrane. It helps maintain the highly folded structure of the inner membrane, known as the cristae, while also supporting the organisation and activity of proteins involved in oxidative phosphorylation. That makes cardiolipin more than just structural material; changes to it can have knock-on effects on mitochondrial energy production.

This interaction with cardiolipin is central to current theories regarding how SS-31 works.

Why cardiolipin matters

Under conditions of mitochondrial stress, cardiolipin can become oxidised. This can interfere with membrane organisation and the normal behaviour of mitochondrial proteins. One area of interest is the relationship between cardiolipin and cytochrome c, a protein involved in electron transport that can also contribute to oxidative damage when its interaction with cardiolipin changes.

Research suggests that elamipretide binds to cardiolipin and alters these interactions. Rather than simply behaving like a conventional antioxidant that sweeps up free radicals, newer work suggests its effects may be more closely connected to changes in mitochondrial membrane properties, protein organisation and electron transport.

That distinction is worth making. Early descriptions of SS-31 often focused heavily on its antioxidant activity. More recent research presents a broader picture in which mitochondrial structure and bioenergetics appear to be important parts of the mechanism.

In practical research terms, investigators have been interested in whether SS-31 could help mitochondria maintain membrane potential, support oxidative phosphorylation and reduce inappropriate production of reactive oxygen species.

SS-31 and mitochondrial energy production

ATP production depends on a chain of reactions taking place across the inner mitochondrial membrane. If the respiratory chain becomes inefficient, cells can struggle to meet their energy requirements.

Preclinical research has reported that elamipretide can influence mitochondrial respiration, membrane stability and ATP production in different experimental models. Studies have looked at tissues with high energy demands, including cardiac and skeletal muscle, as well as other organs affected by mitochondrial dysfunction.

There has also been human research. In one randomised study involving healthy older adults with reduced mitochondrial function, a single dose of elamipretide increased the measured mitochondrial ATP production capacity shortly after administration. The effect was not sustained at day seven, and the study did not demonstrate a significant improvement in muscle fatigue resistance.

That is an interesting finding, but it should not be stretched into a claim that SS-31 improves physical performance or reverses age-related decline. The study was small, short-term and focused on a laboratory measure of mitochondrial function.

What has clinical research found?

SS-31 has moved beyond cell and animal research and has been tested in human clinical trials, particularly in mitochondrial disorders.

Earlier work in people with primary mitochondrial myopathy produced some encouraging signals. In the MMPOWER-2 crossover trial, participants receiving short-term subcutaneous elamipretide showed improvements in several patient-reported measures of fatigue and muscle symptoms. The difference in the six-minute walk test did not reach statistical significance, however.

A larger Phase 3 study, MMPOWER-3, provided a more important test of the compound. The trial involved 218 people with genetically confirmed primary mitochondrial myopathy and compared 24 weeks of elamipretide with placebo. The study did not meet its two primary endpoints: change in six-minute walk distance and total fatigue score. The investigators reported that treatment was generally well tolerated, with most adverse events described as mild to moderate.

Later post-hoc analysis has suggested that certain genetic subgroups may have responded differently, particularly people with nuclear DNA variants affecting mitochondrial DNA maintenance. Those findings are exploratory and were generated after the main trial, so they need to be tested prospectively rather than treated as established clinical evidence.

Where does SS-31 research stand?

The picture is therefore more complicated than some online descriptions suggest.

SS-31 has a well-established biological rationale, a unique mitochondrial target and a substantial body of preclinical research behind it. Its potential is under active investigation in conditions affecting mitochondrial structure, oxidative phosphorylation and energy production.

Although lab results have been promising, they have not always translated to positive results in the clinic. The negative results of MMPOWER-3 are an important point when it comes to reading claims about SS-31 and human mitochondrial disease.

From a research perspective, SS-31 must be considered an experimental mitochondria-targeted peptide and not as a proven therapy or a general supplement. The interaction of SS-31 with cardiolipin, its influence on mitochondrial bioenergetics, and its possible role in various mitochondrial disorders are all matters of active scientific investigation.

For anyone reviewing SS-31 literature, the most useful distinction is between what has been demonstrated in laboratory models, what has been observed through specific human biomarkers, and what has actually translated into meaningful clinical outcomes. Those three things are not interchangeable.